Mesoblast begins subject enrolment in Phase III back pain treatment trial

Australia-based Mesoblast has begun subject enrolment in the Phase III clinical trial of rexlemestrocel-L for patients with chronic low back pain (CLBP) caused by inflammatory degenerative disc disease.